Johnson & Johnson Stock – Fundamental Analysis
Fundamental Data & Ratios (Balance sheet update: 9/18/2026)
| Balance Sheet | Total Assets | 199,210,000,000.00 | ROE | 40.93 % |
| Balance Sheet | Total Equity | 81,544,000,000.00 | ROA | 13.46 % |
| Cashflow | Capital Expenditures | -4,832,000,000.00 | P/FCF | 31.32 |
| Cashflow | Free Cash Flow | 19,697,999,872.00 | – | – |
| Cashflow | Operating Cash Flow | 24,530,000,000.00 | P/CF | 25.15 |
| Income | Earnings per Share (diluted) | 11.03 | Div. Yield | 2.02 % |
| Income | Net Income | 26,804,000,000.00 | P/E | 23.02 |
| Income | Shares Outstanding | 2,429,400,000.00 | P/B | 7.56 |
| Income | Total Revenue | 94,193,000,000.00 | P/S | 6.55 |
Ratios calculated on: 10/14/2026
Company Description
Johnson & Johnson is a holding company. The Company is engaged in the research and development, manufacture and sale of a broad range of products in the health care field. The business of Johnson & Johnson is conducted by more than 275 operating companies located in 60 countries, including the United States, which sell products in virtually all countries throughout the world. In March 2013, Johnson & Johnson's Cordis Corporation announced the acquisition of Flexible Stenting Solutions, Inc. In June 2013, Johnson & Johnson announced the opening of the Johnson & Johnson Innovation center in Boston. In August 2013, Johnson & Johnson announced it has completed its acquisition of Aragon Pharmaceuticals, Inc., a pharmaceutical discovery and development company focused on drugs to treat hormonally driven cancers.
Additional comparison and history views are available after login.
Finanzoo GmbH assumes no liability for the accuracy of the information provided! All information is provided without guarantee. Sources: www.bundesanzeiger.de, www.sec.gov, www.jnj.com
All metrics and scores are an automated evaluation and not investment advice or a recommendation to buy or sell. Finanzoo GmbH or its shareholders may themselves hold positions in the securities shown.
Learn more